USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: BORON BIOLOGICALS, INC.
City: RALEIGH
State: NC
Zip+4: 27606
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (919) 832-2044

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $902,328.00 14
SBIR Phase II $2,966,531.00 6

Award List:

OLIGONUCLEOTIDES WITH BORONATED PHOSPORUS BACKBONES

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

NOVEL BASE BORONATED OLIGONUCLEOTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: DOE
Principal Investigator: Dr Bernard F Spielvogel , Principal Investigator
Award Amount: $50,000.00

NOVEL BASE BORONATED OLIGONUCLEOTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: DOE
Principal Investigator: Dr Bernard F Spielvogel , Principal Investigator
Award Amount: $499,885.00
Abstract:
Boron neutron capture therapy (bnct) has a clear theoreticaladvantage over other techniques as a method of delivering cell killing radiation to tumors. new boron compounds are needed that can selectively localize in tumors and, upon capture of thermal or epithermal neutrons, produce radiationto kill… More

NEW BORON CONTAINING AMINO ACIDS AND PEPTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: DOE
Principal Investigator:
Award Amount: $50,000.00

OLIGONUCLEOTIDES WITH BORONATED PHOSPORUS BACKBONES

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $483,554.00
Abstract:
The objective is to define novel oligonucleotides that have pendant groups containing boron attached to phosphorus in the phosphodiester backbone. such boronated oligonucleotides may function as designed recognition molecules and bind to selected polynucleotide sequences yet impart useful… More

NEW BORON CONTAINING AMINO ACIDS AND PEPTIDES FOR BORON NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: DOE
Principal Investigator:
Award Amount: $500,000.00
Abstract:
Boron neutron capture therapy (bnct) has a clear theoreticaladvantage over other techniques as a method of delivering cell-killing radiation to tumors. new boron compounds are needed which can selectively localize in tumors and upon capture of thermal or epithermal neutrons, produce radiation which… More

NUCLEOSIDE PHOSPHATE ANALOGUES WITH BORONATED PHOSPHATES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Spielvogel, Bernard F , Principal Investigator
Award Amount: $49,944.00

INEXPENSIVE PATHWAYS FOR THE SYNTHESIS OF BORONOPHENYLALANINE AND NEW BORON CONTAINING AGENTS

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: DOE
Principal Investigator: Dr Bernard F Spielvogel , Principal Investigator
Award Amount: $50,000.00

INEXPENSIVE PATHWAYS FOR THE SYNTHESIS OF BORONOPHENYLALANINE AND NEW BORON CONTAINING AGENTS

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: DOE
Principal Investigator: Dr Bernard F Spielvogel , Principal Investigator
Award Amount: $500,000.00
Abstract:
Boron neutron capture therapy (bnct) has a clear theoreticaladvantage over other techniques as a method of delivering cell-killing radiation to cancerous tumors. compounds containing the element boron, such as boronophenylalanine (bpa), can also selectively localize in skin cancers such asmalignant… More

NEW GADOLINIUM-BORON COMPOUNDS FOR NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: DOE
Principal Investigator: Dr. Bernard F. Spielvogel
Award Amount: $50,000.00

NUCLEOSIDE PHOSPHATE ANALOGUES WITH BORONATED PHOSPHATES

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Spielvogel, Bernard F , Principal Investigator
Award Amount: $483,092.00
Abstract:
Use of nucleoside phosphates as antitumor and antiviral agents has been limited by their inability to penetrate cell membranes as well as their high susceptibility to enzymes such as phosphatases, nucleotidases, etc. modification of the phosphate group (by replacing one of the nonbridging oxygens… More

NEW GADOLINIUM-BORON COMPOUNDS FOR NEUTRON CAPTURE THERAPY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: DOE
Principal Investigator: Dr. Bernard F. Spielvogel
Award Amount: $500,000.00
Abstract:
Neutron capture therapy is a very promising therapy for certain tumors, such as gliomas and melanomas. several nuclei have high cross sections for thermal neutrons, of which boron-10 ((10)b) and gadolinium-157 ((157)gd) have been shown to be very promising. (10)b has a high cross section for thermal… More

Amine-Boranes as New Topoisomerase II Inhibitors

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard F. Spielvogel
Award Amount: $50,000.00
Abstract:
The main objective of the research is to develop a new class of topoisomerase II (Topo II) inhibitors as antineoplastic agents. In preliminary studies, heterocyclic amine-carboxyboranes have been shown to possess cytotoxic activity against a number of murine and human tumor tissue culture lines, e.… More

Boronated Nucleoside Bases

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard F. Spielvogel
Award Amount: $50,000.00
Abstract:
We will design and synthesize novel nucleic acid base derivatives containing cyanoborane group attached to a pyridine-type nitrogen atom of the purine or the pyrimidine cycle. The cyanoboronated bases may be designed to be more membrane soluble than the respective 2'- deoxyribonucleosides of known… More

Boronic Acid Analogs of Nucleoside-5'-Phosphates

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard F. Spielvogel
Award Amount: $50,000.00
Abstract:
A major problem with the use of nucleoside phosphates as antiviral and antitumor drugs has been their inability to penetrate cell membranes. Additionally, nucleoside phosphates are susceptible to phosphatases and nucleases, which reduce their in vivo life time. Replacement of the charged phosphate… More

Boronated Asparagine and Glutamine Analogs for BNCT

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard Spielvogel
Award Amount: $79,380.00
Abstract:
Boron Neutron Capture Therapy (BNCT) has a clear theoretical advantage over other techniquesas a method of delivering cell-killing radiation to tumors. The inability of leukemia cells to synthesizeasparagine and the requirement of exogeneous asparagine by tumor cells provide an excellentopportunity… More

Reproductive Toxicology of Boron Analogs of Biomolecules

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard Spielvogel
Award Amount: $73,004.00
Abstract:
Boron analogs of biomolecules exhibit considerable therapeutic potential in the areas of cancertreatment, bone disorder (such as osteoporosis), hyperlipidemia and inflammation. Considerable activityhas been demonstrated in cell cultures and rodent models. Most of the agents tested for acute… More

Selective Silver Staining of DNA Probes

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard Spielvogel
Award Amount: $100,000.00
Abstract:
The major impediment to the wide implementation of DNA diagnostic methods is their cost. Technologisimplify current DNA diagnostic methods and to make them cost competitive with antibody based assaysdesirable. Our new selective silver staining technology could dramatically enhance the… More

P-Carboranylalanine Analogs of BPA for NCT

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Anup Sood
Award Amount: $100,000.00
Abstract:
Boron Neutron Capture Therapy (BNCT) is a very promising therapy for certain tumors, such as gliomamelanomas. p-Boronophenylalanine (BPA), an analog of phenylalanine, is one of the leading BNCT agentundergoing clinical trials in the U.S. for the treatment of gliomas and melanomas. It has already… More

NEW (B22H22)2 FOR NEUTRON CAPTURE AND DIAGNOSTICS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bernard F. Spielvogel
Award Amount: $100,000.00
Abstract:
Not Available Pacific Advanced Technology (PAT) will bring over ten years of experience in spectral imaging to this effort to develop a low cost, lightweight, visible spectral imaging system that will enhance visibility during hazy and low visibility conditions. This will be done by exploiting the… More